News

X-Chem will use the DEL services platform along with a group of new diverse lead- and drug-like small molecule compounds to help expedite the hits’ discovery and to

Kingray Capital, TigerYeah Capital, Morningside Venture Capital, and Trinity Innovation Fund joined the Series Pre-A funding, while FountainBridge Capital participated as the angel investor. Epigenic will utilise the

This drug is intended for the treatment of hallucinations and delusions related with Alzheimer’s disease psychosis (ADP). The CRL showed that the FDA has finished review of the

Vixarelimab has been designed to target oncostatin M receptor beta (OSMRβ) that mediates the interleukin-31 (IL-31) and oncostatin M (OSM) signalling. IL-31 and OSM are two important cytokines

Under the collaboration, the company will partner with the MD Anderson scientists on preclinical trials for further validating TransCode’s RNA-targeted oncology therapy and diagnostic candidates. They will also

Omidubicel is an advanced NAM-enabled stem cell therapy candidate which is being developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for blood cancer

The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D

This licence enables the least developed, low-income, lower middle-income as well as Sub-Saharan African countries to access the long-acting HIV prevention medicine. The deal will give the selected

Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,